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Physiologically Based Pharmacokinetics
and Cancer RiskAssessment
by Melvin E. Andersen'and Kannan Krishnan2
Physiologically based pharmacokinetic (PBPK)modelinginvolvesmathematicallydescribingthecomplexinterplayof
thecritical physicochemical andbiologicaldeterminants involvedinthedispositionofchemicals. Inthisapproach, the
bodyisdividedintoanumberofbiologicallyrelevanttissuecompartments, arrangedinananatomicallyaccurateman-
ner,anddefinedwithappropriaephysiologicalcharacteristic Theextapolationofpharmaconeicbehaviorofeas
from high dosetolow doseforvarious exposureroutesandspeciesispossiblewiththisapproach becausethesemodels
aredevelopedbyintegrating quantitative information onthecriticaldeterminntsofcemi dispositionunderabiological
modelingframework. TheprincipalapplicationofPBPKmodelsisinthepredictionoftissuedosimetryoftoxicmoiety
(e.g., parent chemical, reactive metabolite, macromolecular adduct) of a chemical. Such an application has been
demonstrated with dichloromethane, a liver and lung carcinogen in the B6C3F~mouse. The PBPK model-based risk
assessmentapproachestimatedacancerrisktopeopleof3.7x10-8foralifetimeinhalationexposureof1Ag/m3, which
islowerby morethantwoordersofmagnitudethanthatcalculatedbytheU.S. EnvironmentalProtectionAgencyusing
thelinearizedmultistagemodel(forlow-doseextrapolation) andbodysurfacecorrectionfactor(forinterspeciesscaling).
Thecapability ofpredictingthetarget tissue exposure totoxic moiety in peoplewith PBPKmodelsshould helpreduce
the uncertainty associated with theextrapolation proceduresadopted inconventional dose-response assessment.
Introduction
The process ofrisk assessment for chemical carcinogens is
conducted in four parts: hazard identification, dose-response
assessment, exposure assessment, andriskcharacterization (1).
Dose-response assessment entails both high-dose to low-dose
andinterspeciesextrapolation ofthetissue response. These ex-
trapolations areusually conductedwith "mandated" models, a
linearizedmultistage (LMS) cancermodelforthelowdose, and
a body surface or body weight correction for interspecies ex-
trapolation (2). In the LMS model, the independent variable,
dose, is most usually regarded simply as administered dose or in-
haledconcentrationduringthebioassay exposureperiod. Low-
doseextrapolation activities consistoftheextrapolation ofboth
tissuedosimetry and response. Nonlinearities ineither orboth
ofthese processes can influencethe tumoroutcomedepending
onwhetherthemechanismoftumorinduction isdose-invariant.
The assessment ofrisk associated with exposure to chemicals
shouldbebased onallthebiologically relevantmechanisticdata,
and notsimply onthe administered dose, thusenabling a more
accurate estimation of actual risk. This paper discusses the
methodological aspects ofextrapolating tissue dosimetry with
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theuseofphysiologicalpharmacokinetic modelsandpresentsan
example ofuse of such a model to improve the assessment of
tumorigenic riskassociated with human exposureto dichloro-
methane.
Physiologically Based
Pharmacokinetic Modeling
Physiologicallybasedpharmacokinetic(PBPK)modelingin-
volvesthecomputersimulationoftheuptakeanddispositionof
chemicals based on their blood and tissue solubility
characteristics, metabolism and protein binding in various
tissues, and physiology ofthe organism. The tissue compart-
mentsinthesemodelsareinterpretableinbiologicalterms, thus
enabling interspecies scaling by substitution of parameter
estimates with appropriate values for any species of interest.
Once formulated by integrating information on these critical
biologicaldeterminantsofdisposition,thePBPKmodelscanbe
used to simulate the kinetic behavior ofa chemical in the test
species. Modelsimulationsofpercentdoseexhaled, amountof
metabolites produced, level of hepatic and extrahepatic
glutathionedepletion, tissueandbloodconcentrationsofparent
chemicalanditsmetabolitesetc., canbegeneratedforexposure
scenarios ofinterest. When the model adequately predicts the
pharmacokinetic behavior ofa chemical over a variety ofex-
posuresituations,itisconsideredtobe"validated" andusedfor
high-dose to low-dose and exposure-route extrapolation of
chemicaldispositioninthetestspecies. TheanimalPBPKmodel
can then be used for interspecies extrapolation of phar-
macokineticbehaviorofachemicalbyscalingthephysiologicalANDERSENANDKRISHNAN
parameters anddeterminingthebiochemicalparameters inthe
species ofinterest. Limited validation studies are necessary to
verify the adequacy ofthe model description for the species of
interest.
Failureofamodel toaccurately predictthepharmacokinetic
behaviorofachemical indicates incompleteunderstandingofthe
critical processes involved in its uptake, distribution, metabo-
lism, andelimination. Insuchcases, furtherexperimentation to
obtain informationofaspecific naturetorefineandvalidatethe
model mightbe required(3). The steps involvedinthedevelop-
mentofPBPK models andtheiruse in interspecies scaling and
riskassessment are schematically presented in Figures 1 and2.
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FIGURE 1. Schematic representation ofthedevelopment ofphysiologically bas-
ed pharmacokinetic (PBPK) models forchemicaldispositionin atestspecies.
The principal application of PBPK models is to predict the
tissuedosimetry ofthetoxic moiety (i.e., parentchemical, active
metabolite, macromolecular adduct, etc.). Quantitative informa-
tion onthedoseoftheactive formofachemical intargettissues
provides abetterbasis forextrapolation. Because PBPKmodels
allow theprediction oftargettissuedosimetry inpeoplebased on
physiological andmechanisticconsiderations, they canalsohelp
reduce the uncertainty ofextrapolation procedures adopted in
conventional risk assessment approaches. Such an application
has already been demonstrated with dichloromethane (4).
PBPK Models In Cancer Risk
Assessment: Dichloromethane
Dichroromethane (DCM; methylene chloride; CH2Cl2)
causes significant increases in the incidence ofliver and lung
tumors in B6C3F, mice after inhalation of2000 or 4000 ppm
for 6 hr/day, 5 days/week for 2 years (5). The toxic moiety
responsible for DCM tumorigenicity has not been identified;
however, it is known thatpotentially reactive intermediates are
produced by two major metabolic pathways (6-8). DCM is
metabolized in both target organs by a cytochrome
P-450-mediated oxidative pathway that yields formyl chloride
and by conjugation with glutathione (GSH) yielding
chloromethyl glutathione. UsingthePBPKmodelingapproach,
information on tissue dosimetry of parent chemical and its
metabolites inthe most sensitive test species (i.e., mouse) was
obtained (4). Target-tissueexposuretoanappropriatedosesur-
rogatewas related tothetumorlevels seenintheNational Tox-
icology Program(NTP)bioassay toderivetheacceptabletarget
dose and external exposure concentration for humans. These
predictions werethencomparedtothoseobtainedwiththecon-
ventional risk assessment approach adopted by the U.S. En-
vironmental Protection Agency (U.S. EPA).
Model Development
The PBPKmodel forDCM consistedofthe following tissue
compartments: liver, lung, fat, slowly perfused tissues, and
richlyperfusedtissues. TherateofchangeintheamountofDCM
inthetissuecompartments (dA,/dt) wasdescribedby aseries of
mass-balance differential equations ofthe following form:
dAildt = Qi(Ca-Cvi)-dAmet/dt
whereQiistherateofbloodflowtotissuei(L/hr); Caisthecon-
centration ofDCM inarterialblood (mg/L); Ci1 isthe concen-
tration ofDCM in the venous blood leaving the tissue (mg/L);
dAmt/dtistherateoftheamountofDCM metabolized (mg/hr).
The rateoftheamountofDCM metabolizedperunittime in
the liver and lung was described by accounting for both
microsomal oxidation, asaturableprocess, and GSH conjuga-
tion, afirst-orderprocess, atallexposureconcentrationsusedin
the NTP cancerbioassay:
dAmet/dt = VmaxCv/(Km +Cvj) +KfCvjVi
where V. isthe maximumenzymaticreaction rate(mg/hr); Km
isthe Michaelisconstantforenzymereaction (mg/L); Kfis the
first-order rate constant for GSH conjugation (hr-'); Vi is the
volumeofthetissue (L).
The physiological parameters required for the PBPK model
(i.e., alveolarventilation rate, bloodflow rates, tissuevolumes)
were obtained from the literature (9,10). The blood:air and
tissue:airpartitioncoefficientsforDCMweredeterminedbyvial
equilibrationtechniques(11,12). Thetissue:bloodpartitioncoef-
ficients required for the model were determined by dividing
tissue:air values by the blood:air value. The rate constants for
DCM metabolism weredeterminedbyapportioningthewhole-
bodymetaboliccapacitybetweenlungandliverbyassumingthat
thedistributionofenzymeactivitiesmetabolizingDCM wasthe
sameasthedistributionofenzymeactivitiesactingontwomodel
substrates, 7-ethoxycoumarin for microsomal oxidation, and
2,5-dinitrochlorobenzene for GSH conjugation (13).
The mousePBPKdescription, oncevalidatedby comparing
model predictions with observed pharmacokinetic data, was
scaledtopredictthetissuedosimetryofDCManditsmetabolites
inhumans. Thiswasaccomplishedbyscalingthephysiological
parameters of the model and determining chemical-specific
parameters forhumans. Thus, thetissue: bloodpartition coef-
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FIGURE 2. Schematic representation of the use of physiologically based pharmacokinetic (PBPK) modeling in interspecies extrapolation and risk
assessment.
ficients forhumans werecalculatedbydividingmousetissue:air
partitioncoefficients by humanblood:airpartitioncoefficient.
Further, themetabolicrateconstants forhumanswereestimated
fromvolunteerhumanexposurestudies, inwhichlevelsofDCM
and carboxyhemoglobin in blood were determined during and
following a6-hrexposure to 100 and350ppm DCM (14). The
glutathioneS-transferaseactivity(GST) inhumanswassetequal
to the highest activity reported in rodents.
Choice ofDose Surrogate
ThemousePBPKmodelforDCM, formulatedbyintegrating
information on mouse physiology, DCM solubility character-
istics, and metabolic rate constants, was successfully used to
describe thedisposition ofDCM (4). Themouse PBPKmodel
was then used to calculate the tissue dose ofmetabolites and
parentchemical arisingfromexposurescenarioscomparable to
those of the NTP bioassay studies. Their relationship to the
observed tumorincidence wasexamined. BecauseDCM isvery
unreactive, it is unlikely to be directly involved in its tumor-
igenicity. Hencetherelationshipbetweenthetissueexposureto
its metabolites and tumor incidence was examined (Table 1).
Whereasthedosesurrogatebasedontheoxidativepathwaydid
not vary between DCM exposure concentrations of2000 and
4000 ppm, the flux through the GSH conjugationpathway did
correspondwellwiththedegreeofDCM-induced canceratthese
Table 1. Tumor incidenceandcalculated tissuedoseofdichioromethane
(DCM) metabolitesfollowinginhalation exposuresofDCMinfemalemice.
DCM exposure, Tumor Tissue dose, mg/Ltissue/day
Tissue ppm incidence, % GSH pathway Oxidative pathway
Liver 0 6 - -
2000 33 851 3575
4000 83 1800 3701
Lung 0 6 - -
2000 63 123 1531
4000 85 256 1583
GSH, glutathione. Adapted fromAnderson etal. (4.)
exposureconcentrations. Theseobservationsareconsistentwith
a role for the metabolite(s) arising from the GSH conjugation
pathway inDCM-inducedlungandlivercancer. TheGSHcon-
jugation of DCM, reported to be mediated by a new class of
glutathioneS-transferaseenzymes(15), yieldsformaldehydeas
ametabolite. Recently, Casanovaetal. (16)havereportedDNA-
formaldehyde-protein crosslinks from DCM exposure, further
strengtheningthecasefortheGSHconjugation asthepathway
leading topotentially carcinogenicmetabolites. Therefore, the
high-dosetolow-doseextrapolationandinterspeciesextrapola-
tionofDCM-inducedcancerriskwereconductedwiththetissue
dose of the GSH-pathway metabolite predicted by the PBPK
model.
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FIGURE 3. Dichioromethane tissue-dose assessment: low-dose and interspecies
extrapolation. Estimation oflivertissuedosefo~rdichloromethane glutathione
conjugates with a physiologically based pharmacokinetic model. Reproduced
with permission from Applied Industrial Hygiene (32).
High-Dose to Low-Dose Extrapolation
The model prediction ofthe target tissue dose ofthe DCM-
GSH conjugate resulting from 6-hr inhalation exposures of
1-4000ppmofDCM ispresented in Figure 3. Theestimationof
target tissue dose of DCM-GSH conjugate by linear back-
extrapolation gives risetoa21-fold higherestimatethanthatob-
tainedbythePBPK modeling approach. This discrepancy arises
fromthe nonlinear behaviorofDCMmetabolismathigh expo-
sure concentrations. Atexposure concentrations exceeding 300
ppm, the cytochrome P-450-mediated oxidationpathway is sat-
urated, giving risetoacorrespondingdisproportionate increase
in the flux through the GSH conjugation pathway.
Interspecies Extrapolation
The interspecies extrapolation ofDCM disposition behavior
was possible because the critical biological determinants of
disposition were first identified in the test species, the mouse.
Thus, the physiological parameters were scaled allometrically,
the metabolicparameters weredetermined experimentally and
the tissue:air partitioning ofDCM was assumed tobe species-
invariant. The PBPK model adequately simulated the blood
levels ofDCM observed in humans after a 6-hr inhalation ex-
posure to 100or 350ppmDCM (Fig. 4). The targettissuedose
for humans was estimated to be some2.7 times lower than that
forthemouse. Considering thesedata, thehumantissuedoseof
DCM-GSHconjugate fora6-hrexposureto 1 ppmDCM isex-
pectedtobe some57times lowerthanthatexpectedby linearex-
trapolation ofitsbehaviorathigh doses, such as thedoses used
in the mouse bioassay (4).
Risk Assessment
ThecancerriskassessmentforDCMwasconductedusingthe
LMS model to relate tissue dose of DCM-GSH metabolite
(rather than DCM exposure concentration) to the observed
10.00
0
1.00
co
S
v
0
C
*- 0.10
0.01
- -~~~~~~~~~~~~~~
U
I I
I x
I e
.0 5 10 15 20 25 30 35
Time (hr)
FIGURE 4. Comparison ofmodel simulations (solid lines) with the observed
dataonblooddichloromethanelevelsinhumansduringandafter6-hrinhala-
tionexposuresof100ppm(U)or350ppm(L) . Reproduced with permis-
sion from ToxicologyandAppliedPharmacology (4).
tumor incidence rates at high exposure concentrations in the
mouse. Inassessingthetumorigenicrisksassociatedwithhuman
exposuretothischemical, itwasassumedthathumansareassen-
sitiveasthemostsensitivetargetspecies. Therefore, equaltarget
tissue doses are expected to produce similar tumor incidence
regardlessofthespecies. Thisconclusionisincontrasttothatob-
tainedbytheEPA, whichestimatesthatpeoplearemoresensitive
thanmice, basedon theuseofa surface-area scaling approach
(17). In the human DCM risk assessment based on the PBPK
model usingthe GSTpathway dose, thepredictedhuman low-
lose cancer risk was about 100- to 200-fold less than that esti-
matedbytheEPAusingtheirstandarddefaultassumptions(4).
Withfurtherrefinementofthemodelwiththeestimationofthe
metaboliterateconstantsfbrhumansinvitro, Reitzetal. (18), us-
ing the delivered dose calculated with the PBPK model,
predicted a cancer risk of3.7 x 10 -8 for a lifetime inhalation
exposure of 1 W/m3. This risk estimate is still lower, by more
than two orders ofmagnitude, than thatcalculatedby the EPA
(4.1 x 10-6) using the default assumptions and exposure con-
centration of DCM. The EPA has amended its original risk
assessmentforDCM(19)andincorporatedsome, butnotall, of
theconceptsusedinthephysiologicalpharmacokinetics-based
riskassessmentapproachoutlinedhere.
TheuseofPBPKmodelsinquantitativeriskassessmentdoes
notalwaysresultintheestimationoflowerriskthantheconven-
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tional approach adopted by the EPA. For example, ifthe test
chemical actsdirectly, thePBPKapproachcouldactuallypredict
morerisktohumansthantorodentsbecauseenzyme-mediated
metabolicclearance(detoxification)isexpectedtobelowerinthe
largerspecies. Similarly, ifthetoxicityofachemicalismediated
byreactiveintermediate(s) resultingfromasaturablemetabolic
process, thenthehigh-dosetolow-doseextrapolationconducted
withthePBPKmodelingapproachwouldpredictagreaterrisk
at low doses than that predicted by the linear extrapolation
procedure.
Issues Surrounding the Use of PBPK
Models in RiskAssessment
ThemotivationforuseofPBPKmodelsintoxicologyresearch
is to uncover the biological determinants oftissue dosimetry.
Thesemodelsarepartofasystematicapproachtostudyinghow
chemicals gain entry to, distribute within, and are eliminated
from the body. These models are complex with multiple
parameters, butinthisregardtheysimplyreflectsomeoftheob-
vious complexities ofthebiological system.
Onestrategy foraccuratelyestimatingspecificparameters is
to conduct kinetic studies under conditions where phar-
macokineticbehaviorofchemicalsisrelatedtooneortwodomi-
nant factors and thereby derive estimates ofthe value ofthese
parameters. An example is the estimation of metabolic
parameters by gas uptake studies (20). Alternatively,
biochemicalandchemical-specific parameters maybedirectly
estimated insomecases fromstudieswithinvitropreparations
(18) or obtained from theliterature (21).
Parameteridentifiabilityandmodeloverspecificationareprob-
lems inherent in these PBPK models or in any other multi-
parametermodel. Directmeasurementofmodelparametersby
experimental methods, independent ofanalysis oftissuetime-
coursecurves, isthepreferred approach. Nonetheless, limited
numbers ofparameters will often still have to be estimated by
analysis oftime-coursedatabycurve-fittingtechniques, under
well-definedexperimental conditionswherethecurvesarepar-
ticularly sensitive to the parameterofinterest.
Otherareasofconcernrelatetotheadequacyofthemodelin
biological terms. Areallimportantbiologicaldeterminantsofthe
uptakeanddispositionofthetestchemicalincludedinthemodel
description? For riskassessment, some additionaluncertainty
surroundsthedecisionregardingwhichmeasureoftissuedose
bestcorrelates withtumorformation. Forinstance, istheGSH
conjugation with DCM really the key determinant in DCM
tumorigenesis? These are essentially biological, research-
orientedissueswhoseanswersrelyonknowledgeofmechanisms
oftoxicity andcarcinogenicity ofaparticular chemical.
Anotherconcernintheareaofextrapolationtohumansisthe
useofpointestimatesofmodelparameters insteadofapplying
a distribution of parameter values to develop ranges of risk
estimates (22). This issue deserves serious attention from a
generic pointofview, not solely as itapplies to PBPK model-
based assessments. Presentinterspecies scaling takes littleac-
countofvariabilityinpopulationcharacteristicstoderiveranges
ofrisk. The impact ofvariability in interspeciesextrapolation
needstobeconsideredforbothdefaultprocedures(theLMSpro-
cedure, bodysurfacecorrection, etc,)andforthecaseofPBPK
model-basedassessmentssuchastheoneproposedwithDCM.
Despitetheseunresolved issues, PBPKmodelsarebecoming
morewidespreadinmanyareasoftoxicology research(23,24).
We arebeginning to seemoreexamples ofapplication ofthese
models fortheassessmentoftumorigenic riskassociated with
humanexposuretochemicals (25-27). ThePBPKmodelingad-
dresses only the tissue dose aspect ofthe exposure-dose-re-
sponsecontinuum. Detailedknowledgeofallaspectsofthecon-
tinuum is required to improve risk assessment. The PBPK
model-basedriskassessmentshaveusedthesemodelstoestimate
tissuedosebutstillrelyonLMSapproachastheresponsemodel.
Biologicallybasedresponsemodelsarealsobeingdevelopedfor
useinriskassessment(28,29). Fullylinkeddosimetry-response
simulation models promise to integrate a diversity of phar-
macokinetic, mechanistic, andtumorprogressionstudies intoa
unitarydescriptionofchemicalcarcinogenesis(30,31). Thesein-
tegratedbiological modelsshouldgreatlyimprovethescientific
basis of low-dose and interspecies extrapolation of tissue
dosimetry and response.
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